Galectin-9与CXCL10作为幼年皮肌炎疾病活动度生物标志物的验证研究
本研究在125例幼年皮肌炎患者中验证Galectin-9和CXCL10作为疾病活动度生物标志物,并评估其疾病特异性和预测复发能力。结果显示两者在区分活动期与缓解期方面优于肌酸激酶,且可在症状出现前数月提示复发。
要点
- Galectin-9和CXCL10区分活动期与缓解期的AUC为0.86-0.90,优于CK的0.66-0.68。
- Galectin-9敏感度0.84、特异度0.92;CXCL10敏感度0.87、特异度1.00。
- 连续升高或上升的生物标志物水平可在症状出现前数月提示复发。
核心结论
- Galectin-9和CXCL10被验证为幼年皮肌炎疾病活动度的敏感可靠生物标志物,可能有助于个性化治疗。
研究设计与样本
- 研究纳入125例幼年皮肌炎患者,来自3个国际横断面队列和1个本地纵向队列,采用多重免疫分析检测血清Galectin-9和CXCL10水平。
- 在50例成人皮肌炎或非特异性肌炎患者和61例其他系统性自身免疫病患者中检验两种蛋白的疾病特异性。
主要发现
- 横断面和纵向上,Galectin-9和CXCL10区分幼年皮肌炎活动期与缓解期的AUC为0.86-0.90,优于肌酸激酶的AUC 0.66-0.68。
- Galectin-9对活动期的敏感度和特异度分别为0.84和0.92,CXCL10分别为0.87和1.00。
- 10例前瞻性随访的幼年皮肌炎复发患者中,持续升高或上升的生物标志物水平可在症状出现前数月提示即将复发,即使肌酸激酶未升高。
- Galectin-9和CXCL10可区分成人皮肌炎或非特异性肌炎的活动期与缓解期(Galectin-9 P=0.0126,CXCL10 P<0.0001)。
- 两种蛋白适用于微创干血斑检测(健康对照 vs 幼年皮肌炎,Galectin-9 P=0.0040,CXCL10 P<0.0001)。
关键数值与推荐
- Galectin-9区分幼年皮肌炎活动期与缓解期的AUC为0.86-0.90,敏感度0.84,特异度0.92。
- CXCL10区分幼年皮肌炎活动期与缓解期的AUC为0.86-0.90,敏感度0.87,特异度1.00。
- 肌酸激酶区分活动期与缓解期的AUC为0.66-0.68。
- 成人皮肌炎或非特异性肌炎活动期与缓解期比较:Galectin-9 P=0.0126,CXCL10 P<0.0001。
- 干血斑检测健康对照与幼年皮肌炎比较:Galectin-9 P=0.0040,CXCL10 P<0.0001。
临床怎么用
- Galectin-9和CXCL10可作为幼年皮肌炎疾病活动度监测工具,辅助指导治疗决策。
- 连续监测生物标志物水平可能有助于预测复发,提前数月提示 flare。
- 干血斑微创检测方式便于临床随访应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Objective evaluation of disease activity is challenging in patients with juvenile dermatomyositis (DM) due to a lack of reliable biomarkers, but it is crucial to avoid both under- and overtreatment of patients. Recently, we identified 2 proteins, galectin-9 and CXCL10, whose levels are highly correlated with the extent of juvenile DM disease activity. This study was undertaken to validate galectin-9 and CXCL10 as biomarkers for disease activity in juvenile DM, and to assess their disease specificity and potency in predicting the occurrence of flares. METHODS: Levels of galectin-9 and CXCL10 were measured by multiplex immunoassay in serum samples from 125 unique patients with juvenile DM in 3 international cross-sectional cohorts and a local longitudinal cohort. The disease specificity of both proteins was examined in 50 adult patients with DM or nonspecific myositis (NSM) and 61 patients with other systemic autoimmune diseases. RESULTS: Both cross-sectionally and longitudinally, galectin-9 and CXCL10 outperformed the currently used laboratory marker, creatine kinase (CK), in distinguishing between juvenile DM patients with active disease and those in remission (area under the receiver operating characteristic curve [AUC] 0.86-0.90 for galectin-9 and CXCL10; AUC 0.66-0.68 for CK). The sensitivity and specificity for active disease in juvenile DM was 0.84 and 0.92, respectively, for galectin-9 and 0.87 and 1.00, respectively, for CXCL10. In 10 patients with juvenile DM who experienced a flare and were prospectively followed up, continuously elevated or rising biomarker levels suggested an imminent flare up to several months before the onset of symptoms, even in the absence of elevated CK levels. Galectin-9 and CXCL10 distinguished between active disease and remission in adult patients with DM or NSM (P = 0.0126 for galectin-9 and P < 0.0001 for CXCL10) and were suited for measurement in minimally invasive dried blood spots (healthy controls versus juvenile DM, P = 0.0040 for galectin-9 and P < 0.0001 for CXCL10). CONCLUSION: In this study, galectin-9 and CXCL10 were validated as sensitive and reliable biomarkers for disease activity in juvenile DM. Implementation of these biomarkers into clinical practice as tools to monitor disease activity and guide treatment might facilitate personalized treatment strategies.
引用
- Wienke J, Bellutti Enders F, Lim J, et al. Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation. Arthritis Rheumatol. 2019. PMID: 30861625. doi:10.1002/art.40881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。